Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The biological effects of structural variation at the meta position of thearomatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors
Autore:
Xu, GZ; Micklatcher, M; Silvestri, MA; Hartman, TL; Burrier, J; Osterling, MC; Wargo, H; Turpin, JA; Buckheit, RW; Cushman, M;
Indirizzi:
Purdue Univ, Sch Pharm & Pharm Sci, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA Purdue Univ W Lafayette IN USA 47907 Pharmacol, W Lafayette, IN 47907 USA So Res Inst, Infect Dis Res Dept, Frederick, MD 21701 USA So Res Inst Frederick MD USA 21701 Dis Res Dept, Frederick, MD 21701 USA
Titolo Testata:
JOURNAL OF MEDICINAL CHEMISTRY
fascicolo: 24, volume: 44, anno: 2001,
pagine: 4092 - 4113
SICI:
0022-2623(20011122)44:24<4092:TBEOSV>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
VIRUS TYPE-1 HIV-1; LOW-VALENT TITANIUM; ANTIRETROVIRAL THERAPY; SELECTIVE-INHIBITION; COMBINATION THERAPY; ADAM SERIES; COENZYME-A; RESISTANCE; INFECTION; PHARMACOKINETICS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
53
Recensione:
Indirizzi per estratti:
Indirizzo: Cushman, M Purdue Univ, Sch Pharm & Pharm Sci, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA Purdue Univ W Lafayette IN USA 47907 W Lafayette, IN 47907 USA
Citazione:
G.Z. Xu et al., "The biological effects of structural variation at the meta position of thearomatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors", J MED CHEM, 44(24), 2001, pp. 4092-4113

Abstract

In an effort to elucidate a set of structure-activity relationships in thealkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptaseinhibitors, a number of modifications were made at two locations: (1) the meta positions of the two aromatic rings and (2) the end of the alkenyl chain. Forty-two new ADAMs were synthesized and evaluated for inhibition of the cytopathic effect of HrV-1(RF) in CEM-SS cell culture and for inhibition of HIV-1 reverse transcriptase. The size of the aromatic substituents was found to affect anti-HIV activity, with optimal activity appearing with Cl, CH3, and Br substituents and with diminished activity occurring with. smaller (H and F) or larger (I and CF3) substituents. The substituents at the end of the alkenyl chain were also found to influence the antiviral activity,with maximal activity associated with methyl or ethyl ester groups and with diminished activity resulting from substitution with higher esters, amides, sulfides, sulfoxides, sulfones, thioesters, acetals, ketones, carbamates, ureas, and thioureas. Twelve of the new ADAMs displayed submicromolar EC50 values for inhibition of the cytopathic effect of HIV-1(RF) in CEM-SS cells. Selected ADAMs, 19 and 21, were compared to previously published ADAMs 15 and 17 for antiviral efficacy and activity against the HIV-1 reverse transcriptase enzyme. All four ADAMs were found to inhibit HIV-1 reverse transcriptase enzyme activity, to inhibit the replication of a variety of HIV-1 clinical isolates representing syncytium-inducing, nonsyncytium-inducing, and subtype representative isolates, and to inhibit HIV-1 replication in monocytes. Subsequent assessment against a panel of site-directed reverse transcriptase mutants in NL4-3 demonstrated no effect of the K103N mutation on antiviral efficacy and a slight enhancement (6- to 11-fold) in sensitivity to AZT-resistant viruses. Additionally, ADAMs 19 (44-fold) and 21 (29-fold)were more effective against the A98G mutation (found in association with nevirapine resistance in vitro), and ADAM 21 was 5-fold and 2-fold more potent against the Y181C inactivation mutation than the previously reported ADAMs 15 and 17, respectively. All four ADAMs were tested for efficacy againsta multidrug-resistant virus derived from a highly experienced patient expressing resistance to the reverse transcriptase enzyme inhibitors AZT, ddI, 3TC, d4T, foscarnet, and nevirapine, as well as the protease inhibitors indinavir, saquinavir, and nelfinavir. ADAM 21 was 2-fold more potent than ADAM 15 and 6-fold more potent than ADAMs 17 and 19 at preventing virus replication. Thus, we have identified a novel series of reverse transcriptase inhibitors with. a favorable profile of antiviral activity against the primarymutation involved in clinical failure of non-nucleoside reverse transcriptase inhibitors, K103N, and that retain activity against a multidrug-resistant virus.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 00:08:14